Myungmoon Pharm명문제약
017180 · KOSPI · ₩017180 · 명문제약
- Market cap
- ₩39B
- Enterprise value
- ₩51B
- P/E
- —
- P/B
- 0.4×
- Dividend yield
- 0.0%
- ROE
- −1.7%
- Net margin
- −0.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−44.0% from the high
₩1,000Today: ₩1,130 – ₩1,167₩2,055
Returns
- 1W−6.7%
- 1M−7.6%
- 3M+8.8%
- 6M−35.7%
- YTD−37.8%
- 1Y−28.2%
- Volume today
- 65,208
- 0.8× the 20-day average
- Traded today
- ₩74M
- Listed shares
- 33,953,454
- EPS (12 months)
- −₩49
- Earnings yield −4.3%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 38 of 100 (50 is a normal day for this stock).
- SentimentMixedNews: Routine insider shareholding filings with no clear positive or negative news. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-6.9% over the last month; the price is below its 20-day average.
- News impactLow4 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Myungmoon Pharm stock overview
Myungmoon Pharm (명문제약, KRX: 017180) is listed on KOSPI, in the Biotech & Pharma sector. , Ltd. Its shares closed at ₩1,150 on Oct 29, 2026, down 1.12% on the day, giving it a market value of ₩39B.
Key facts
- Market cap
- ₩39B
- Sector
- Biotech & Pharma
- Latest price change
- −1.12%
- As of
- Oct 29, 2026
- Main business
- , Ltd.
Quick answers about Myungmoon Pharm
- What does Myungmoon Pharm do?
- , Ltd. is a Korean pharmaceutical company that manufactures and sells finished and raw pharmaceutical products and distributes medicines, operating through its pharmaceutical and bio segment, and also runs a service segment covering golf courses and real estate development through its subsidiary. Its main products include cholesterol-lowering drugs such as Rosuzet and Myungmoon Rosuvastatin, along with other prescription medicines, and it sells mainly in Korea with a smaller share of exports.
- What is the market cap of Myungmoon Pharm?
- The market capitalisation of Myungmoon Pharm was ₩39B at the close on Oct 29, 2026.
- Who are the largest shareholders of Myungmoon Pharm?
- According to the latest official filings, the largest reported holders are Woo Seok-min (21.59%, as of Apr 30, 2026); Bae Cheol-han (1.00%, as of Nov 24, 2025); Jeong Joon-il (0.84%, as of Oct 27, 2026).
- When is the next earnings report from Myungmoon Pharm?
- Korean companies rarely announce results dates in advance. Based on when Myungmoon Pharm filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Myungmoon Pharm?
- Yes. The National Pension Service held 0.30% of Myungmoon Pharm shares as of Dec 31, 2025.
Company profile
Myungmoon Pharm Co., Ltd. is a Korean pharmaceutical company that manufactures and sells finished and raw pharmaceutical products and distributes medicines, operating through its pharmaceutical and bio segment, and also runs a service segment covering golf courses and real estate development through its subsidiary. Its main products include cholesterol-lowering drugs such as Rosuzet and Myungmoon Rosuvastatin, along with other prescription medicines, and it sells mainly in Korea with a smaller share of exports. The company's manufacturing facilities are located in Hwaseong, Gyeonggi Province, and its golf and related services operate in Icheon, Gyeonggi Province.
Written by AI from the company's latest annual report.
- Korean name
- 명문제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 배철한
- Founded
- Sep 1983
- Listed
- Jul 2008
- Listed shares
- 33,953,454
- Fiscal year ends
- Month 12
- Website
- www.mmpharm.co.kr
Similar companies
- Samsung Biologics207940 · ₩63T₩1,366,000−0.44%
- Celltrion068270 · ₩44T₩189,300−0.26%
- Alteogen196170 · ₩15T₩220,000−1.35%
- SK biopharmaceuticals326030 · ₩6.1T₩77,800+3.46%
- Yuhan000100 · ₩5.5T₩74,700−3.36%
- HLB028300 · ₩5.3T₩39,700−2.34%
- Hanmi Pharm128940 · ₩5T₩388,500+5.14%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,600−0.74%
Recent filings
See all- Insider shareholding reportOct 27, 2026
- Insider shareholding reportOct 27, 2026
- Insider shareholding reportOct 19, 2026
- Insider shareholding reportOct 19, 2026
- Insider shareholding reportOct 7, 2026
Titles in Korean until English translations are added.
Also known as: Myungmoon Pharm / 명문제약 / 017180 / KRX:017180
Source: KRX statistical information